Company profile

Mammoth

Mammoth, a San Francisco-based CRISPR diagnostics company, has raised $271 million across multiple rounds, including a $150 million Series D led by Redmile Group and Foresite Capital. With a $1 billion valuation (as of September 2021), the company leverages Cas12 and Cas13 proteins to develop next-gen molecular diagnostics for healthcare, agriculture, and industrial applications. Backed by top investors like Mayfield, Decheng Capital, and the National Institutes of Health, Mammoth aims to redefine disease detection and gene-based therapeutics through precision CRISPR technology.

Back to profiles

Quick facts

Total funding: $271 million
Valuation: $1 billion

Notable investors

Decheng Capital
Redmile Group
Foresite Capital

Reach buyers like Mammoth on TexAu

TexAu helps go-to-market teams find, enrich, and reach companies that match this profile. Pick the path that fits how you work.

Find companies like Mammoth
Build a list by industry, headcount, funding stage, or technographics. Get verified emails and direct dials.
Start a free workspace
Enrich your CRM with company data
Push funding, headcount, hiring signals, and tech stack into HubSpot, Salesforce, or a spreadsheet. Waterfall enrichment.
See how the waterfall works
Run it on a schedule
Refresh the list weekly, score new accounts as they land, and push the ones that fit to Smartlead, Instantly, Lemlist, HeyReach, or Apollo Sequences.
See how schedulers work

Reach buyers like Mammoth.

The 14-day trial ships every feature, no card required.

Start free →